BioIntelliSense, Inc. — SEC Form D Filing

BioIntelliSense, Inc. filed an SEC Form D on December 19, 2025, reporting $58.05M raised in Health Technology.

Form D filing details

Filing
SEC Form D
Filing date
December 19, 2025
Amount reported
$58.05M
Round stage
Series B+
Industry
Health Technology
Website
https://www.biointellisense.com/

What the company does

Securities: Equity, Offering of Preferred Stock and the underlying shares of Common Stock issuable upon conversion of Preferred Stock.. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Hospitals and healthcare providers struggle with efficiently and continuously monitoring patients, both in-facility and at home, leading to delayed detection of deterioration and increased operational burdens.

Solution

BioIntelliSense provides a wearable device that continuously monitors vital signs and biometrics, coupled with a dashboard for analysis, to proactively identify patient decline and improve outcomes.

Why now

The increasing demand for remote patient monitoring, value-based care models, and the need for operational efficiency in healthcare due to staffing shortages and rising costs drive the adoption of continuous monitoring solutions.

Source: SEC EDGAR Form D filing